While the Outperform rating suggests that Baird continues to view Biomarin Pharmaceutical positively, the reduction in the price target could imply a tempered expectation for the stock's growth or a recalibration of valuation metrics. This news is likely to have a neutral short-term impact on the stock price as the positive sentiment from the Outperform rating may be offset by the lowered price target.